BAY43-9006 Phase II Study for Renal Cell Carcinoma
Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
To evaluate efficacy, safety, and pharmacokinetics of BAY 43-9006 in patients with
unresectable and/or metastatic renal cell cancer (RCC) who have failed at least one cytokine
containing regimen.